Company
The Radiopharmaceutical industry leader in Korea
A fast growing biotech company with proven records
What we have done and where we are
Developing new Radiopharmaceuticals for cancer diagnosis and treatment
The core of the industry is providing competitive research technology proven by the optimized radiochemical yield.
-
The Top
Top sales in every product line in Korea
-
The First
The first Korean company to export
-
The Largest
The largest product portfolio and pipeline in the country
-
The Only
The only developer of GEP-NET Therapeutic Radiopharmaceutical in Korea
-
Stable
Stable and largest
RP-manufacturing network in Korea -
Representative
Representative Radiopharmaceutical company in Korea
Radiopharmaceutical specialized ‘Open Innovation’ platform
Development of new drugs with competitive technology proven by the optimized
Radiochemical yield, achieving successful commercialization
Creating virtuous cycle
- Leading Radiopharmaceutical industry
- Building up of global network
- Developing and licensing new drugs
Competitive Advantages in Business-driven Intellectual Properties
Intellectual Properties of DCB
| Patent/Trademark | Patents | Trademark | Remarks | ||||
|---|---|---|---|---|---|---|---|
| 25/1 | Domestic | International | Domestic | PCT Application : 5 |
|||
| Pending | Registered | Pending | Registered | Pending | Registered | ||
| Total | - | 25 | 13 | 15 | - | 1 | |
Market Share (%)
First-mover and No.1 in market share in each product
-
FDG
0 % -
FP-CIT
0 % -
Neuraceq
0 %
(Source: MFDS “Integrated Information System”, 2019)
Greetings from Duchembio CEO
The passion to challenge a new market
where everything is a beginning!
With our experience in Korea,
we will pursue the passion in Southeast Asia
